Leland Stanford Junior University

Sutro Biopharma, Inc.

Sunesis Pharmaceuticals, Inc.

Foresee Pharmaceuticals Usa, Inc.

Merck Sharp + Dohme Corp.

Gilead Sciences, Inc.

Foresee Pharmaceuticals Co., Ltd.

Aviv Therapeutics, Inc.

Stanford University

Wenjin Yang

Daria D Mochly-Rosen

Che-Hong Chen

Christopher D Thanos

Jeffrey S Glenn

Ryan Stafford

Robert S McDowell

Ingrid Choong

Shirit Einav

Kai-Wei Chang

Hadas Dvory-Sobol

Wanli Lu

Suying Liu

Choung U Kim

Lawrence R McGee

Craig Alan Coburn

Melissa S Egbertson

Shaun R Stauffer

Qun Yin

Norbert W Bischofberger

Cheng-Han Tsai

Michael J Postich

Steven H Krawczyk

Georgia B McGaughey

Bruce Fahr

Harold G Selnick

Samuel L Graham

Kenneth Jay Barr

Jeffrey William Jacobs

James C Barrow

Min Zhong

Shawn J Stachel

Philippe G Nantermet

Brian C Cunningham

Hemaka Anthony Rajapakse

Brian Raimundo

Lou Anne Neilson

Kenneth E Rittle

Zhi-Qiang Yang

Melody McWherter

William Michael Flanagan

Jiang Zhu

Douglas R Cary

Nathan D Waal

Yafan Lu

Jian Sun

Jennifer Wilkinson

Yie-Teh Yu

Chun Jiang

David Cory

Daria Mochly-rosen

Robert Mcdowell

Teh-Yie Yu

Hemaka A Rajapakse

Georgia B Mcgaughey

Melody A Mcwherter

Shawn R Stachel

Hydantoin based compounds of formula (I) useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

Matrix metalloproteinase (MMP) inhibitors and methods of use thereof

Provided herein are modified amino acids comprising an azido group, polypeptides, antibodies and conjugates comprising the modified amino acids, and methods of producing the polypeptides, antibodies and conjugates comprising the modified amino acids. The polypeptides, antibodies and conjugates are useful in methods of treatment and prevention, methods of detection and methods of diagnosis.

Modified amino acids

Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

Hydantoin based compounds of formula (I) useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis. 

Provided herein are modified amino acids comprising a tetrazine groups according to Formula I: polypeptides, antibodies, payloads and conjugates comprising these modified amino acid residues derived from the modified amino acids, and methods of producing the polypeptides, antibodies, payloads and conjugates comprising the modified amino acid residues. The polypeptides, antibodies, payloads and conjugates are useful in methods of treatment and prevention, methods of detection and methods of diagnosis. 

Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use

The present disclosure provides compounds of formula (I) that function as modulators of mitochondrial aldehyde dehydrogenase-2 (ALDH2) activity, and methods of preparing these compounds.

Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof

The present invention provides compounds that bind to mitochondrial aldehyde dehydrogenase-2 (ALDH2), methods of using said compounds to treat patients with Fanconi Anemia, and methods of preparing said compounds.

Mitochondrial aldehyde dehydrogenase-2 binding compounds and methods of use thereof

Growing community of inventors

Foster City, CA, United States of America

Wenjin Yang